Pompano Beach, FL, October 17, 2018 -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, today announced that it has engaged PCG Advisory Group, a leading investor relations and digital strategies firm, to serve as an advisor for investor relations and strategic communications.
“Through our three operating subsidiaries, BioStem has been executing on its strategic growth plans and we have a number of upcoming catalysts and milestones,” said Henry Van Vurst, CEO of BioStem. “To ensure that the investment community is aware of these important events and their impact on the growth of BioStem, we’ve partnered with PCG for a strategic investor relations and digital media program. We believe that PCG has the right combination of contacts, skills and strategies to assist us in reaching our goals.”
“We look forward to working with BioStem, where momentum has been building as the Company pursues multiple avenues for growth. Through our long experience with biotech clients, PCG’s seasoned team has the experience and expertise to raise BioStem’s awareness and visibility with the investment community,” said Jeff Ramson, CEO of PCG Advisory Group.
About BioStem Technologies, Inc.
BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value. For more information, go to: www.biostemtechnologies.com
About PCG Advisory Group
Founded in 2008, PCG Advisory is dedicated to the delivery of top-tier strategic advisory services that encompass investor and stakeholder relations, capital markets navigation, corporate communications and social media management for emerging growth companies. The team at PCG has extensive experience with life science, fintech and blockchain technology and works with innovative and emerging companies from around the globe. As an aggregation, distribution, and engagement platform, PCG reaches thousands of individual, retail and institutional investors and stakeholders in its proprietary and extensive distribution network, and through the use of unique digital marketing and audience development techniques. For more information, go to: www.pcgadvisory.com
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.
Facebook: BioStem Technologies
Andrew Van Vurst, COO
Chuck Harbey, Managing Director
PCG Advisory Group